First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
• Takeda’s manufacturing site at Lessines, Belgium, is contributing to the production of the clinical material for the NIH Phase 3 trial, emphasizing the importance of Belgium as a pharmaceutical hub.

Read the rest of this article in our digital newsletter